Major Growth Influencing Factors:

The antimicrobial susceptibility testing (AST) market is expanding due to a number of causes, including the increased frequency of infectious diseases, the high level of antibiotic resistance, and the government’s supportive efforts to reduce the burden of infectious diseases. Antibiotic resistance testing is becoming more common as a result of an increase in certain ailments, including bloodstream infections and pneumonia caused by K. pneumonia, P. aeruginosa, and E. coli, among others.

Projected Surge in Revenue Generation:

According to revenue estimates, the global market for antimicrobial susceptibility testing was valued at $3.6 billion in 2022 and is expected to increase at a compound annual growth rate (CAGR) of 5.5% to reach $4.7 billion by 2027.

Download PDF Brochure@

Challenge: Intricate regulatory structures

One of the main issues with antimicrobial susceptibility testing is the delay that occurs between the definition of clinical breakpoints, the approval of innovative antimicrobial treatments, and the release of these medications onto the market. The FDA establishes certain thresholds when drug companies submit applications for new medications that are denied. The absence of clinical breakpoints for some drugs further hinders the adoption of antimicrobial susceptibility solutions. For instance, no clinical cutoffs are known to assess the effectiveness of antifungal treatment for invasive mold infections other than Aspergillus infections.

Opportunity: Prospects for expansion in developing economies

Players in the antimicrobial susceptibiity testing market have a lot of chances in emerging nations like APAC, China, India, and Japan. The market for antimicrobial susceptibility testing is expanding in these nations due to the quick rise in medical tourism, the population expansion of adults (those over 20), and the rise in drug usage. These nations are also home to a workforce that is highly skilled and knowledgeable about cutting-edge technologies.These nations are also underdeveloped in most areas and have lax import/export regulations, which may aid businesses in building their brands. The regions are benefiting from a growing number of technicians who are eager to learn about new technologies and who are upgrading their skills.

End Users:

During the projection period, the antimicrobial susceptibility testing industry is predicted to develop at the fastest rate by End User, specifically hospitals and diagnostic centers.

With a 63.5% market share in 2022, hospitals and diagnostic centers will hold a greater portion of the antimicrobial susceptibility testing market. At a CAGR of 5.7% over the course of the forecast period, this end-user segment is expected to grow from USD 2.2 billion in 2022 to USD 2.9 billion in 2027. Over the course of the projection period, this end-user category is anticipated to rise at the highest CAGR of 5.7%.

Geographical Growth Scenario:

Throughout the projection period, North America is anticipated to hold the top spot in the antimicrobial susceptibility testing market.

North America holds the largest share of the global market for antimicrobial susceptibility testing (35.4%). America is made up of the US and Canada. North America has the largest proportion due to the rising number of ailments for which pre-tests are necessary, the aging population, and the emergence of novel virus, fungus, and bacterial strains there. Owing to an increase in drug addiction, abuse, and noncompliance, the Asia-Pacific region is growing at the fastest rate—6.7%.

Request Sample Pages@

Key Players:

As of 2021, prominent players in the market are include bioMérieux SA (France), Becton, Dickinson, and Company (US), Thermo Fisher Scientific (US), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US) among others.

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledgestore” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]